Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients (COMED)

This study has been completed.
Kantonsspital Aarau
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland Identifier:
First received: September 30, 2011
Last updated: November 30, 2015
Last verified: November 2015

Background: Hypo- and hypernatremia are common in hospitalized patients. The differential diagnosis of dysnatremia is challenging.

Osmotically inadequate secretion of antidiuretic hormone (ADH) is the predominant mechanism in most dysnatremic disorders. ADH measurement is cumbersome. It is derived from a larger precursor peptide along with copeptin, which is a more stable peptide directly mirroring the production of ADH.

Objective: To evaluate the additional value of copeptin to improve a currently used algorithm in the differential diagnosis of (A) severe hypoosmolar hypo- and (B) severe hypernatremia.

Design: Prospective observational study.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • diagnostic accuracy of copeptin within hospital stay [ Time Frame: participants will be followed for up to 1 year ] [ Designated as safety issue: No ]
    diagnostic accuracy will be determined by receiver operated curve (ROC) analysis. The study is powered to detect a difference of copeptin levels between patients with partial central diabetes insipidus (DI) and patients with primary polydipsia.

Enrollment: 300
Study Start Date: October 2011
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
hospitalized patients
hospitalized patients with hyponatremia


Ages Eligible for Study:   18 Years to 110 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
hospitalized patients with severe hypo or hypernatremia

Inclusion Criteria:

  • hyponatremia <125 or hypernatremia >155 mmol/L

Exclusion Criteria:

  • no informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01456533

Beat Müller
Aarau, Aargau, Switzerland
Mirjam Christ-Crain
Basel, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Kantonsspital Aarau
Principal Investigator: Mirjam Christ-Crain, MD, PhD University Hospital, Basel, Switzerland
Principal Investigator: Beat Müller, MD Kantonsspital Aarau, University Hospital Basel
  More Information

Responsible Party: University Hospital, Basel, Switzerland Identifier: NCT01456533     History of Changes
Other Study ID Numbers: COMED Study 
Study First Received: September 30, 2011
Last Updated: November 30, 2015
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Basel, Switzerland:

Additional relevant MeSH terms:
Water-Electrolyte Imbalance
Metabolic Diseases processed this record on October 26, 2016